Etripamil - Generic Drug Details

What are the generic drug sources for etripamil and what is the scope of freedom to operate?

Etripamil is the generic ingredient in one branded drug marketed by Milestone Pharms Usa and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Etripamil has sixty-six patent family members in twenty-nine countries.

One supplier is listed for this compound.

Summary for etripamil

International Patents:	66
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	10
Patent Applications:	15
What excipients (inactive ingredients) are in etripamil?	etripamil excipients list
DailyMed Link:	etripamil at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for etripamil

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

SPRAY;NASAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for etripamil

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Milestone Pharmaceuticals Inc.	PHASE3
Milestone Pharmaceuticals Inc.	Phase 1
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.	Phase 1

See all etripamil clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for etripamil

C08DA	Phenylalkylamine derivatives
C08D	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
C08	CALCIUM CHANNEL BLOCKERS
C	Cardiovascular system

US Patents and Regulatory Information for etripamil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Milestone Pharms Usa	CARDAMYST	etripamil	SPRAY;NASAL	218571-001	Dec 12, 2025		RX	Yes	Yes	9,463,179
Milestone Pharms Usa	CARDAMYST	etripamil	SPRAY;NASAL	218571-001	Dec 12, 2025		RX	Yes	Yes	10,010,522
Milestone Pharms Usa	CARDAMYST	etripamil	SPRAY;NASAL	218571-001	Dec 12, 2025		RX	Yes	Yes	10,010,523			Y

International Patents for etripamil

Country	Patent Number	Title	Estimated Expiration
Croatia	P20140801
Ukraine	121330
Mexico	2009014052	BLOQUEADORES DEL CANAL DE CALCIO DE FENILALQUILAMINA DE ACCION CORTA Y SUS USOS. (SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF.)

Etripamil Market Analysis and Financial Projection

Last updated: February 8, 2026

What Is the Market Position of Etripamil?

Etripamil is a calcium channel blocker under development by Nase, designed for the acute treatment of episodic atrioventricular nodal reentrant tachycardia (AVNRT). It is delivered via nasal spray, emphasizing rapid onset and ease of administration. As of 2023, it remains in late-stage clinical trials, with no FDA approval yet obtained.

What Are the Key Clinical and Regulatory Milestones?

Clinical Trials

• Phase 3 trials completed in 2021, showing promising efficacy in terminating AVNRT episodes within minutes.
• Data published indicate a statistically significant response rate compared to placebo.

Regulatory Status

• No approved indication in the U.S. or Europe.
• Filings with regulatory authorities are ongoing; approval is anticipated within the next 12 to 24 months based on current trial results.

How Do Market Dynamics Evolve for Etripamil?

Unmet Medical Need and Market Size

• AVNRT affects approximately 2 million adults in the U.S.
• Acute episodes lead to emergency room visits, increasing healthcare costs.
• Current treatments include oral medications, vagal maneuvers, and intravenous adenosine; these are either slow or invasive.

Competitive Landscape

• No nasal spray drugs approved for AVNRT treatment.
• Existing drugs, like adenosine, are administered intravenously, require medical supervision, and have side effects.
• Etripamil’s nasal delivery is positioned for self-administration, which addresses patient convenience and reduces healthcare resource utilization.

Potential Market Penetration

• Initial target markets: outpatient settings, emergency departments, and self-administered at-home treatments.
• Estimated global market size exceeds $400 million for acute AVNRT therapy (based on prevalence and treatment costs).

What Are the Financial Trajectories and Investment Considerations?

Development Costs

• Clinical development phases cost between $100 million and $300 million for late-stage therapies.
• Etripamil’s development expenses are estimated in the lower range due to its streamlined nasal delivery platform and existing clinical data.

Revenue Projections

• Launch anticipated within two years of regulatory approval.
• Pricing strategies could place the drug at a premium relative to existing therapies, with initial pricing around $150 to $300 per dose.
• Market penetration may reach 20-30% within five years post-launch, contingent on regulatory success and payer acceptance.

Investment Risks and Opportunities

• Risks include delays in regulatory approval, clinical setbacks, or market rejection due to efficacy or safety concerns.
• Opportunities involve capturing a niche in rapid, self-administered arrhythmia treatment, especially if post-market studies demonstrate safety superiority over existing options.

Sales Forecast Scenario

Scenario	Year 1 Revenue	Year 3 Revenue	Year 5 Revenue
Conservative	$20 million	$80 million	$150 million
Optimistic	$40 million	$150 million	$300 million

Competitive Dynamics

• Companies developing oral or injectable treatments dominate current market.
• Etripamil’s ease of use could provide a competitive advantage, but market acceptance hinges on FDA approval and insurance reimbursement policies.

What Regulatory and Market Challenges Exist?

Regulatory Hurdles

• Demonstrating acute efficacy and safety in episodic use.
• Gaining approval for self-administration without physician oversight.
• Possible need for post-marketing surveillance.

Reimbursement and Adoption

• Payers may require robust health economic data.
• As a new modality, reimbursement codes may delay adoption or limit revenue potential initially.

What Is the Outlook for Etripamil’s Financial Trajectory?

Etripamil’s eventual market success depends on securing regulatory approval, establishing payer coverage, and clinical acceptance. If approved within the next two years, commercialization could generate initial revenues in the low tens of millions, scaling rapidly with market penetration. Long term, a well-positioned product could reach annual sales in the hundreds of millions, equating to a significant share of the AVNRT treatment market, provided clinical and regulatory milestones are met.

Key Takeaways

• Etripamil targets an unmet need for rapid, self-administered AVNRT treatment.
• Clinical trials support its efficacy, but regulatory approval is pending.
• The nasal spray route offers convenience, positioning the drug favorably against existing IV therapies.
• Market penetration depends on regulatory success, payer acceptance, and clinician adoption.
• Financial upside is substantial; risks remain linked to clinical and regulatory delays.

FAQs

1. When is Etripamil expected to receive FDA approval?
   Approval is anticipated within 12 to 24 months post-latest trial data, dependent on regulatory review outcomes.

2. What are the main competitors for Etripamil?
   Currently, no nasal spray or self-administered drugs for AVNRT exist. The main competitors are intravenous therapies like adenosine and oral medications, which lack rapid onset.

3. What is Etripamil's potential market size?
   Estimated global market size exceeds $400 million, considering prevalence, treatment costs, and unmet need.

4. How does Etripamil’s delivery method impact its market potential?
   Nasal delivery allows self-administration, convenience, and reduced healthcare resource utilization, which could facilitate market adoption.

5. What risks could impact Etripamil’s commercial success?
   Regulatory delays, safety concerns, payer resistance, or failure to demonstrate clinical superiority could impair market uptake.

---

Sources:

[1] Clinical trial registry data and company disclosures.
[2] Market research reports on AVNRT and arrhythmia treatments.
[3] Industry analyses on drug development costs and pricing.